A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Part of paid clinical trials in Duarte, California.
- Sponsor
- AstraZeneca
- Study ID
- NCT07681596
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- AZD4045 — BIOLOGICALAllogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA)
- Daratumumab — DRUGAnti-CD38 monoclonal antibody
- Aldesleukin — DRUGRecombinant human IL-2
Study Details
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.
Key Dates
- Start date
- Jul 9, 2026
- Status verified
- Jun 2026
- Primary completion
- Oct 30, 2029
- Completion
- Oct 30, 2029
Study Design
- Enrollment
- 101 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Module 1: AZD4045 monotherapy
- Experimental: Module 1: AZD4045 in association with daratumumab and aldesleukin
Primary Outcome Measure
Adverse events (AEs) and serious AEs (SAEs) [ Time Frame: Through study completion, an average of 2 years ]
Central Contacts
- AstraZeneca Clinical Study Information Center1-877-240-9479
Locations (10)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Duarte | California | 91010 | - |
| Research Site | Denver | Colorado | 80218 | - |
| Research Site | Tampa | Florida | 33612 | - |
| Research Site | Atlanta | Georgia | 30322 | - |
| Research Site | St Louis | Missouri | 63110 | - |
| Research Site | Hackensack | New Jersey | 07601 | - |
| Research Site | Cleveland | Ohio | 44195 | - |
| Research Site | Nashville | Tennessee | 37203 | - |
| Research Site | Houston | Texas | 77030 | - |
| Research Site | Milwaukee | Wisconsin | 53226 | - |
Find similar trials in Duarte, CA
Related Studies
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)PHASE3 · Recruiting · Celgene · Los Alamitos, California
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisPHASE1 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaPHASE1 · Recruiting · Jiangsu Simcere Pharmaceutical Co., Ltd. · Phoenix, Arizona
- A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaPHASE1/PHASE2 · Recruiting · ModernaTX, Inc. · Birmingham, Alabama